Applied BioMath, LLC to Present Case Studies on Model-Aided Drug Invention (MADI) at the American Conference of Pharmacometrics (ACoP)

Applied BioMath (, the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation in the upcoming American Conference on Pharmacometrics (ACoP) occurring October 15-18, 2017 in Fort Lauderdale, FL. Applied BioMath will be a conference sponsor, exhibitor, and poster presenter. Applied BioMath’s posters will highlight several examples of model-aided drug invention (MADI) by presenting case studies in immuno-oncology, osteoarthritis, and antibody-drug conjugates. More specifically, they will show:

  • An example of integrating systems modeling to predict optimal drug properties targeting PD-1 and TIM3 in immuno-oncology for bispecific biologics and fixed dose combinations
  • QSP approaches to determine best in class properties for targeted anabolic growth factor to arthritic joints
  • Computational exploration of mechanistic determinants of ADC pharmacokinetics using QSP modeling strategies

“We are excited to share our work with the participants of ACoP again this year,” said Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath. “Our proprietary MADI approach continues its track record of successfully helping biotechnology and pharmaceutical companies better understand their drug candidate’s mechanism of action in the context of human disease mechanisms.”

The  American Conference on Pharmacometrics is just one stop of many on the Applied BioMath Fall 2017 speaking tour. Prior to ACoP, Dr. Burke will be speaking at the World Bispecific Summit as well as the Pharmaceutical and BioScience Society’s QSP event both being held in Boston, MA. Dr. Burke will also be speaking at the Quantitative Systems Pharmacology Industry and Academia Symposium on October 24th being held at the Cambridge Innovation Center in Cambridge, MA. For more information on any of these events, visit

About Applied BioMath

Applied BioMath (, the industry-leader in applying mechanistic modeling to drug research and development, helps biotechnology and pharmaceutical companies answer complex, critical Go/No-go decisions in R&D.    Applied BioMath leverages biology, proprietary mathematical modeling and analysis technology, high-performance computing, and decades of industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, and the best path forward.   Our involvement shortens project timelines, lowers cost, and increases the likelihood of a best-in-class drug.  We provide clarity to complex situations, answer otherwise unanswerable questions, and our approach, when validated in the clinic, is 10x more accurate than traditional methodologies.

Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.

Press contact:

Kristen Zannella